Product Details
Azithromycin
500MG
Product Description :
AZITHROMYCIN INJECTION 500 mg
Sterile Powder for Solution for Intravenous Infusion
COMPOSITION
Each vial contains:
Azithromycin Dihydrate equivalent to Azithromycin ............... 500 mg
Excipients: As applicable.
PHARMACEUTICAL FORM
Sterile, white to off-white powder for solution for intravenous infusion.
THERAPEUTIC CLASS
Macrolide Antibiotic
INDICATIONS
Azithromycin Injection is indicated for the treatment of serious infections caused by susceptible microorganisms when intravenous therapy is appropriate.
It may be used in the treatment of:
• Community-acquired pneumonia
• Pelvic inflammatory disease
• Serious respiratory tract infections
• Certain skin and soft-tissue infections
• Other infections caused by susceptible microorganisms
Treatment should be guided by the susceptibility of the causative organism and applicable antimicrobial guidelines.
CONTRAINDICATIONS
Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, other macrolide or ketolide antibiotics, or any component of the formulation.
DRUG INTERACTIONS
Particular consideration may be required with concomitant use of:
• Warfarin and other anticoagulants
• Digoxin
• Certain antiarrhythmic medicines
• Other medicines that may prolong the QT interval
• Cyclosporine
The treating physician should review all concomitant medications before administration.
ADMINISTRATION
Azithromycin Injection is intended for intravenous infusion only.
The contents of the vial should be reconstituted with a suitable compatible diluent under appropriate aseptic conditions and further diluted before intravenous infusion.
Azithromycin should not be administered as an intravenous bolus or intramuscular injection.
For Intravenous Infusion Only.
STORAGE
Store according to the storage conditions stated on the approved product label.
Protect from excessive heat, moisture and light.
After reconstitution/dilution, use within the period specified in the approved product information.
